Movement Alert｜AstraZeneca Rises 3.06% in Regular Trading, Positive Phase III Liver Cancer Immunotherapy Data Combined with Pharma Sector Strength

Market Focus06-04

On June 4, AstraZeneca rose 3.06% in regular trading, trading at approximately $181.4/share, with trading volume of $82.39 million.

The rally was primarily driven by positive results from the EMERALD-3 Phase III trial announced at the ASCO Annual Meeting. The study demonstrated that Imfinzi (durvalumab) combined with Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolization (TACE) achieved a statistically significant 30% reduction in the risk of disease progression or death versus TACE alone in patients with embolization-eligible unresectable hepatocellular carcinoma. Median progression-free survival reached 13.0 months versus 9.8 months for the control arm. The positive data effectively offset prior negative sentiment from the failed CARES Phase III trial evaluating anselamimab in light chain amyloidosis.

Additionally, the broader pharmaceutical sector rallied on the day, with Eli Lilly up 4.63%, Novo Nordisk up 4.55%, Merck up 3.59%, Johnson & Johnson up 1.96%, and Pfizer up 1.58%, providing further sector-wide tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120452728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120452728","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca Rises 3.06% in Regular Trading, Positive Phase III Liver Cancer Immunotherapy Data Combined with Pharma Sector Strength","media":"Market Focus","content":"<p><p>On June 4, AstraZeneca rose 3.06% in regular trading, trading at approximately $181.4/share, with trading volume of $82.39 million.</p><p>The rally was primarily driven by positive results from the EMERALD-3 Phase III trial announced at the ASCO Annual Meeting. The study demonstrated that Imfinzi (durvalumab) combined with Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolization (TACE) achieved a statistically significant 30% reduction in the risk of disease progression or death versus TACE alone in patients with embolization-eligible unresectable hepatocellular carcinoma. Median progression-free survival reached 13.0 months versus 9.8 months for the control arm. The positive data effectively offset prior negative sentiment from the failed CARES Phase III trial evaluating anselamimab in light chain amyloidosis.</p><p>Additionally, the broader pharmaceutical sector rallied on the day, with Eli Lilly up 4.63%, Novo Nordisk up 4.55%, Merck up 3.59%, Johnson &amp; Johnson up 1.96%, and Pfizer up 1.58%, providing further sector-wide tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca Rises 3.06% in Regular Trading, Positive Phase III Liver Cancer Immunotherapy Data Combined with Pharma Sector Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca Rises 3.06% in Regular Trading, Positive Phase III Liver Cancer Immunotherapy Data Combined with Pharma Sector Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, AstraZeneca rose 3.06% in regular trading, trading at approximately $181.4/share, with trading volume of $82.39 million.</p><p>The rally was primarily driven by positive results from the EMERALD-3 Phase III trial announced at the ASCO Annual Meeting. The study demonstrated that Imfinzi (durvalumab) combined with Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolization (TACE) achieved a statistically significant 30% reduction in the risk of disease progression or death versus TACE alone in patients with embolization-eligible unresectable hepatocellular carcinoma. Median progression-free survival reached 13.0 months versus 9.8 months for the control arm. The positive data effectively offset prior negative sentiment from the failed CARES Phase III trial evaluating anselamimab in light chain amyloidosis.</p><p>Additionally, the broader pharmaceutical sector rallied on the day, with Eli Lilly up 4.63%, Novo Nordisk up 4.55%, Merck up 3.59%, Johnson &amp; Johnson up 1.96%, and Pfizer up 1.58%, providing further sector-wide tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1120452728","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120452728","pubTimestamp":1780583926,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, AstraZeneca rose 3.06% in regular trading, trading at approximately $181.4/share, with trading volume of $82.39 million.The rally was primarily driven by positive results from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"动静提示|阿斯利康常规交易涨3.06%肝癌免疫疗法三期数据利好叠加医药板块走强","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On June 4, AstraZeneca rose 3.06% in regular trading, trading at approximately $181.4/share, with trading volume of $82.39 million.The rally was primarily driven by positive results from the EMERALD-3 Phase III trial announced at the ASCO Annual Meeting. The study demonstrated that Imfinzi (durvalumab) combined with Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolization (TACE) achieved a statistically significant 30% reduction in the risk of disease progression or death versus TACE alone in patients with embolization-eligible unresectable hepatocellular carcinoma. Median progression-free survival reached 13.0 months versus 9.8 months for the control arm. The positive data effectively offset prior negative sentiment from the failed CARES Phase III trial evaluating anselamimab in light chain amyloidosis.Additionally, the broader pharmaceutical sector rallied on the day, with Eli Lilly up 4.63%, Novo Nordisk up 4.55%, Merck up 3.59%, Johnson & Johnson up 1.96%, and Pfizer up 1.58%, providing further sector-wide tailwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120452728","isCrawlerRequest":true}